Arthur A Boni
Dennis M. Gross
Moira A Gunn
Daniel S. Levine

DOI:10.5912/jcb985


Abstract:

This article summarizes our intent and basis for recognition of innovators in our industry, including the criterion that we are using for those organizations selected. Our focus for this year is largely on the Biopharma segment, because of Covid-19 and the positive and significant impact that our industry has made in that regard. We focus on companies across the life cycle from startups ranging to the large multi-national pharma companies.